Jayasinghe Maleesha, Prathiraja Omesh, Caldera Dilushini, Jena Rahul, Coffie-Pierre James Anwar, Silva Minollie Suzanne, Siddiqui Ozair S
Medicine, Nanjing Medical University, Nanjing, CHN.
Medicine and Surgery, Nanjing Medical University, Nanjing, CHN.
Cureus. 2023 Apr 12;15(4):e37509. doi: 10.7759/cureus.37509. eCollection 2023 Apr.
Colorectal cancer (CRC) is a significant cause of morbidity and mortality worldwide. National screening guidelines have been implemented to identify and remove precancerous polyps before they become cancer. Routine CRC screening is advised for people with average risk starting at age 45 because it is a common and preventable malignancy. Various screening modalities are currently in use, ranging from stool-based tests (fecal occult blood test (FOBT), fecal immunochemical test (FIT), and FIT-DNA test), radiologic tests (computed tomographic colonography (CTC), double contrast barium enema), and visual endoscopic examinations (flexible sigmoidoscopy (FS), colonoscopy, and colon capsule endoscopy (CCE)) with their varying sensitivity and specificity. Biomarkers also play a vital role in assessing the recurrence of CRC. This review offers a summary of the current screening options, including biomarkers available to detect CRC, highlighting the benefits and challenges encompassing each screening modality.
结直肠癌(CRC)是全球发病和死亡的重要原因。各国已实施筛查指南,以在癌前息肉发展成癌症之前对其进行识别和切除。建议平均风险人群从45岁开始进行常规CRC筛查,因为这是一种常见且可预防的恶性肿瘤。目前使用的筛查方式多种多样,包括基于粪便的检测(粪便潜血试验(FOBT)、粪便免疫化学试验(FIT)和FIT-DNA检测)、放射学检测(计算机断层结肠成像(CTC)、双重对比钡灌肠)以及视觉内镜检查(乙状结肠镜检查(FS)、结肠镜检查和结肠胶囊内镜检查(CCE)),它们具有不同的敏感性和特异性。生物标志物在评估CRC复发方面也起着至关重要的作用。本综述总结了当前的筛查选择,包括可用于检测CRC的生物标志物,突出了每种筛查方式的益处和挑战。